Pharmacodynamic and Pharmacokinetic Interaction Profile of Vericiguat: Results from Three Randomized Phase I Studies in Healthy Volunteers

BACKGROUND: Vericiguat, a direct stimulator of soluble guanylate cyclase, has been developed as a first-in-class therapy for symptomatic chronic heart failure (HF) and ejection fraction < 45%. METHODS: Safety, pharmacodynamic (PD), and pharmacokinetic (PK) interactions between vericiguat and drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Boettcher, Michael, Loewen, Stephanie, Gerrits, Mireille, Becker, Corina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7932970/
https://www.ncbi.nlm.nih.gov/pubmed/33030703
http://dx.doi.org/10.1007/s40262-020-00935-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7932970/
https://www.ncbi.nlm.nih.gov/pubmed/33030703
http://dx.doi.org/10.1007/s40262-020-00935-6

Ejemplares similares